NCT03375320 2026-03-18Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 1 FDA